Compare ISTR & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ISTR | IVVD |
|---|---|---|
| Founded | 2006 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 372.2M | 437.1M |
| IPO Year | 2014 | 2021 |
| Metric | ISTR | IVVD |
|---|---|---|
| Price | $28.32 | $1.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $29.00 | $8.75 |
| AVG Volume (30 Days) | 123.8K | ★ 3.4M |
| Earning Date | 04-21-2026 | 05-14-2026 |
| Dividend Yield | ★ 1.54% | N/A |
| EPS Growth | 4.41 | ★ 79.02 |
| EPS | ★ 2.13 | N/A |
| Revenue | N/A | ★ $53,426,000.00 |
| Revenue This Year | $66.56 | $61.57 |
| Revenue Next Year | $5.18 | $41.42 |
| P/E Ratio | $13.37 | ★ N/A |
| Revenue Growth | N/A | ★ 110.47 |
| 52 Week Low | $16.31 | $0.49 |
| 52 Week High | $30.49 | $3.07 |
| Indicator | ISTR | IVVD |
|---|---|---|
| Relative Strength Index (RSI) | 57.62 | 55.73 |
| Support Level | $26.18 | $1.41 |
| Resistance Level | $28.95 | $1.77 |
| Average True Range (ATR) | 0.52 | 0.15 |
| MACD | 0.15 | 0.05 |
| Stochastic Oscillator | 73.47 | 83.33 |
Investar Holding Corp is a U.S.-based financial holding company. Through its subsidiaries, it offers a variety of commercial and retail lending products throughout its market areas, including business loans to small to medium-sized businesses, as well as loans to individuals. It has business operations spread across the United States and serves its customers through several service branches. The bank also offers cashiers' checks, direct deposit of payroll and Social Security checks, night depository, bank-by-mail, automated teller machines with deposit automation, and debit cards.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.